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Available online 15 July 2016Traumatic brain injury (TBI) is a major cause of death and disability worldwide, especially in children and young
adults. TBI is an example of a medical conditionwhere there are still major lacks in diagnostics and outcome pre-
diction. Here we apply comprehensive metabolic proﬁling of serum samples from TBI patients and controls in
two independent cohorts. The discovery study included 144 TBI patients, with the samples taken at the time of
hospitalization. The patients were diagnosed as severe (sTBI; n= 22), moderate (moTBI; n= 14) or mild TBI
(mTBI; n= 108) according to Glasgow Coma Scale. The control group (n= 28) comprised of acute orthopedic
non-brain injuries. The validation study included sTBI (n=23),moTBI (n=7), mTBI (n=37) patients and con-
trols (n=27). We show that two medium-chain fatty acids (decanoic and octanoic acids) and sugar derivatives
including 2,3-bisphosphoglyceric acid are strongly associated with severity of TBI, and most of them are also de-
tected at high concentrations in brain microdialysates of TBI patients. Based on metabolite concentrations from
TBI patients at the time of hospitalization, an algorithmwas developed that accurately predicted the patient out-
comes (AUC= 0.84 in validation cohort). Addition of the metabolites to the established clinical model (CRASH),
comprising clinical and computed tomography data, signiﬁcantly improved prediction of patient outcomes. The
identiﬁed ‘TBI metabotype’ in serum, that may be indicative of disrupted blood-brain barrier, of protective phys-
iological response and alteredmetabolism due to head trauma, offers a new avenue for the development of diag-
nostic and prognostic markers of broad spectrum of TBIs.





Traumatic brain injury1. Introduction
Traumatic brain injury (TBI) is a major cause of death and disability
worldwide (Maas et al., 2008), especially in children and young adults.ology, Tykistokatu 6, FI-20520
3@wbic.cam.ac.uk
tylainen@oru.se (T. Hyötyläinen).
pen access article under the CC BY-NClassical approaches to grading TBI rely on the Glasgow coma score
(GCS) (Saatman et al., 2008) and neuroimaging, but this classiﬁcation
takes no account of mechanistic heterogeneity or addresses emerging
approaches to precision medicine (Maas et al., 2015).
TBI is associated with a complex metabolic disruption that results in
energy crisis and energy failure, which is the consequence of multiple
mechanisms, including classical ischaemia (Coles et al., 2004), diffusion
hypoxia (Menon et al., 2004), mitochondrial dysfunction (Lakshmanan
et al., 2010) and increased energy needs (fromexcitotoxicity, seizure ac-
tivity and spreading depolarization) (Timofeev et al., 2011). Thus far,C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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volved the use of cerebrospinal ﬂuid (CSF), brain microdialysis,
arteriojugular venous differences, or advanced metabolic imaging with
positron emission tomography (PET) or magnetic resonance imaging
and spectroscopy (MRIS), none of which are universally available, and
are particularly problematic in less severe TBI. Since metabolic dysregu-
lation is such a fundamental facet of TBI pathophysiology, these meta-
bolic changes may contain prognostic information, and early changes
may provide a useful summary of the pre-hospital and early hospital
physiological insults experienced by the brain. The broad assumption
has been that these metabolic changes are the consequence of metabol-
ic failure – but there is the possibility that somemay be causes aswell as
consequences of the pathophysiology observed. In addition, release of
brain speciﬁc metabolites (i.e. small molecules with molecular mass
under 500 Da) into the systemic circulation may provide information
on blood brain barrier (BBB) dysfunction, a fundamental process in
TBI (Saw et al., 2014).
Several peptide or protein based biomarkers for TBI have been pro-
posed. These include S100 calcium binding protein B (S100B), neuron-
speciﬁc enolase, myelin basic protein, creatine kinase brain isoenzyme,
glial ﬁbrilary acidic protein, plasma DNA, brain-derived neurotrophic
factor, and ubiquitin carboxy-terminal hydrolase-L1 (Berger et al.,
2006; Ingebrigtsen and Romner, 2002; Mondello et al., 2011; Papa et
al., 2010; Pelinka et al., 2004; Vos et al., 2004). However, most of these
biomarkers lack the disease speciﬁcity. For example, protein S100B,
the most extensively studied biomarker of TBI, has been reported to
be released into the serum also after experimental ischemic injury to
the liver, kidney, and the gut (Pelinka et al., 2004). Moreover, its levels
have been found to have increased also after exercise (Koh and Lee,
2014), extracranial trauma (Savola et al., 2004) and burns (Anderson
et al., 2001) and it has also been suggested as a biomarker of melanoma
(Torabian and Kashani-Sabet, 2005).
Here we hypothesized that metabolites may be a rich source of cir-
culating TBI biomarkers.We applied comprehensivemetabolic proﬁling
of serum samples from TBI patients and controls comprised of acute or-
thopedic non-brain injuries in two independent cohorts, with the aims
(a) to associate metabolite proﬁles with TBI severity and (b) to predict
the outcomes of TBI patients.
2. Materials and Methods
2.1. Ethics Statement
South-West Finland Hospital District Research Ethics Committee,
the Cambridgeshire 2 Research Ethics Committee, and the Norfolk
Research Ethics Committee approved the protocol. All patients or
their next of kin were given both oral and written information
about the study and a written informed consent was obtained. All pa-
tients were treated according to standard local guidelines based onTable 1






Mean ±SD (Range) Male/femalea BTH A
Discovery group
(Turku)
Control 28 51.43 20.49 (20–99) 13/15
Mild 108 48.37 20.18 (18–91) 74/34 4 1
Moderate 14 59.57 17.32 (32–88) 8/6 0 3
Severe 22 55.05 15.25 (19–77) 19/3 1 3
Validation group
(Cambridge)
Control 27 42.04 15.81 (18–77) 14/13
Mild 37 36.84 17.95 (16–84) 28/9 5 8
Moderate 7 41.57 20.49 (19–68) 7/0 0 2
Severe 23 44.87 17.71 (20–69) 17/6 4 8
a The proportion of males is signiﬁcantly different between the control and TBI groups in bo
b Mechanismof injury: BTH, blow to head; A/C, acceleration/deceleration; V, violence; GLF, gr
c Computed tomography ﬁndings (CT ﬁndings):−, no visual pathology; +, visual pathologythe current international guidelines and recommendations (Brain
Trauma Foundation et al., 2007).
2.2. Study Population and Clinical Assessment
Patient recruitment of this prospectivemulticenter studywas part of
the EU funded TBIcare (Evidence-based Diagnostic and Treatment Plan-
ning Solution for Traumatic Brain Injuries) project. A total of 389 adult
patients with acute TBI and 81 patients with acute orthopedic trauma
without acute or previous brain disorders, who served as controls,
were prospectively recruited at Turku University Hospital (Turku,
Finland) and at Addenbrooke's Hospital (Cambridge, United Kingdom).
211 patients with acute TBI and 55 orthopedic trauma patients had eli-
gible serum samples available (Table 1).
Inclusion criteria were: age ≥ 18 years (≥16 years in United King-
dom), clinical diagnosis of TBI and indications for acute head computed
tomography according to National Institute for Health and Care Excel-
lence (NICE) criteria (http://www.nice.org.uk/guidance/cg176). Exclu-
sion criteria were: blast-induced or penetrating injury, chronic
subdural hematoma, inability to live independently due to pre-existing
brain disease, TBI or suspected TBI not needing head computed tomog-
raphy, more than two weeks from the injury, not speaking native lan-
guage, and no consent obtained. The control group comprised patients
with acute orthopedic non-trivial trauma without any signs of acute
central nervous system involvement, previous central nervous system
disease, or previous non-concussional TBI.
Two separate sample cohorts were utilized in this study (Turku and
Cambridge studies, respectively). Blood samples for metabolomic anal-
ysis (2 ml) were collected within 12 h after hospital admission. After
sampling, the samples were allowed to clot for 30 min at +4 °C before
centrifugation for 10min at 10,000 rpm at 4 °C. After centrifugation the
serumwas divided into ﬁve aliquots and immediately frozen at−70 °C.
Cerebral microdialysis was undertaken using a CMA71, 100 kDa molec-
ular weight cut-off catheter (M Dialysis AB, Stockholm, Sweden), via a
cranial access device (Technicam, Newton Abbot, United Kingdom),
perfused at 0.3ml/min using a CMA106 pump (MDialysis AB). The per-
fusate consisted of CNS perfusion ﬂuid (M Dialysis AB).
The severity of TBI was classiﬁed on the basis of Glasgow Coma Scale
(GCS) (Saatman et al., 2008). GCS 13–15 was considered mild, 9–12
moderate and 3–8 severe. GCS scores in the scene of accident assessed
by paramedics or an emergency physician were retrieved from the am-
bulance sheets. GCS scores at emergency departmentswere assessed on
admission. Lowest recorded GCS before intubation and sedation from
the scene of accident or emergency department was used in the statis-
tical analysis.
Outcomes were assessed at 3 months in patients with mild TBI
(Cambridge) and at 6–12 months (all other patients) after the injury
using Extended Glasgow Outcome Scale (GOSe), which divides patients
with TBI into groups allowing the standardized assessment of theirism of injuryb CT
ﬁndingsc
Outcome (GOSe score)
/C V GLF FFH HAO O N/A − + Mean ±SD (Range) # with score
8 11 45 23 5 0 2 48 60 6.43 1.87 (1–8) 99
1 6 3 1 0 0 3 11 4.79 2.01 (1–7) 14
0 10 6 0 1 1 0 22 3.47 2.41 (1–7) 19
0 10 6 5 2 1 16 21 7.13 1.48 (3–8) 30
0 1 3 0 1 0 5 2 5.71 2.06 (3–8) 7
0 1 4 6 0 0 0 23 4.38 2.13 (1–8) 16
th the discovery and validation cohorts (χ2 test; p b 0.001).
ound level fall; FFH, fall fromheight; HAO; head against object; O, other; N/A, not available.
(swelling, contusions, mass lesions).
120 M. Orešič et al. / EBioMedicine 12 (2016) 118–126recovery in eight categories (Wilson et al., 1998). GOSe score 5–8 was
classiﬁed as favorable outcome, and GOSe score 1–4 was classiﬁed as
unfavorable outcome.
2.3. Metabolomic Analysis
Metabolomic analyses of serum and brain microdialysate samples
were performed at VTT Technical Research Centre of Finland (Espoo,
Finland). Additional analyses to identify metabolites of interest were
also performed at LECO Corporation (St. Joseph, Michigan) and Steno
Diabetes Center (Gentofte, Denmark).
Serum samples (30 μl) or microdialysate samples (100 μl) were
spikedwith 10 μl of internal standardmixture (C17:0 (186,5mg/l), deu-
terated valine (37 mg/l) and succinic acid-d4 (63 mg/l). The protein
precipitation was done as follows: 400 μl of methanol was added
and then the samples were vortexed for 2 min. After centrifugation
(5 min at 7800 g at room temperature) and settling for 30 min at
−20 °C the supernatant was evaporated to dryness under gentle
ﬂow of nitrogen before derivatization. The original metabolites
were then converted into their methoxime and trimethylsilyl (TMS)
derivatives by two-step derivatization. First, 25 μl of methoxyamine
hydrochloride (98%) was added to the residue, and the mixture was
incubated for 60 min at 45 °C. Next, 25 μl of N-methyl-N-
trimethylsilyltriﬂuoroacetamide was added, and the mixture was
incubated for 60 min at 45 °C. Finally, a retention index standard
mixture (n-alkanes, 25 μl, c = 8 mg/l) and an injection standard (4,4′-
dibromooctaﬂuorobiphenyl, 50 μl, c = 10 mg/l), both in hexane, were
added to the mixture.
GC × GC–TOFMS analyses were carried out on an Agilent 6890 gas
chromatograph equipped with a split/splitless injector (Agilent Tech-
nologies, Santa Clara, CA), cryogenic dual-stage modulator and time-
of-ﬂight mass spectrometer (Leco Corp., St. Joseph, MI, USA). In addi-
tion, multipurpose sampler with Maestro software (Gerstel, Mülheim
an der Ruhr, Germany) was used for derivatization and sample intro-
duction. A 10 m × 0.18 mm I.D. Rxi-5 ms (Restek Corp., Bellefonte, PA,
USA) column with ﬁlm thickness 0.18 μmwas used as the ﬁrst column
and a 1.5 m × 0.1 mm I.D. BPX-50 (SGE Analytical Science, Austin, TX,
USA) columnwith ﬁlm thickness of 0.1 μmas the second column. A phe-
nyl methyl deactivated retention gap column (1.5 m × 0.53 mm I.D.)
was installed in front of the ﬁrst column. The injector was used in the
splitlessmode at 240 °C for injecting 1 μl of a sample. The splitless period
was 90 s. High-purity helium (Aga, Espoo, Finland) was used as the car-
rier gas in a constant-pressure mode with initial pressure of 276 kPa.
The ﬁrst column oven temperature programwas as follows: 50 °C (iso-
thermal for 2 min) then 7 °C/min to 240 °C, and, ﬁnally, 25°/min to
300 °C (3 min). The second dimension column oven temperature was
maintained 20 °C higher and the programming rate and hold times
were similar than in theﬁrst dimension. The temperature of the transfer
linewasmaintained at 260 °C and ion source at 200 °C.Modulation time
was 4 s. Electron impact ionization was applied at 70 eV, and the mass
range from 45 to 700 amu with 100 spectra/s was measured.
Automatic peak detection and mass spectrum deconvolution were
performed using a peak width set to 0.2 s. Peaks with signal-to-noise
(S/N) values lower than 100 were rejected. The S/N values were based
on the masses chosen by the software for quantiﬁcation. ChromaTOF
version 4.32 (LECO Corporation, St. Joseph, MI) was used for the raw
data processing. The peak areas from total ion chromatography (TIC)
were used for most of the compounds; for compounds that were quan-
tiﬁed with the ChromaTOF software, peak areas of selected characteris-
tic m/z were used.
Next, the data ﬁles obtained by the ChromaTOF software were
exported to text ﬁles and in-house developed software Guineu
(Castillo et al., 2011) was used for aligning and normalization of com-
pounds for further analyses. The original GC × GC–TOFMS data includes
retention times, retention indices (RI), spectral information (for possi-
ble identiﬁcation), spectral similarity value (S = 0–999), and peakresponse data. The linear retention indices were calculated based on
the total (i.e., sum of the ﬁrst and the second dimension) retention
times of the compounds and the retention times of the retention
index standards (n-alkanes). The second dimension retention time is
so short (1–3.5 s) that its contribution to the retention index is not sig-
niﬁcant. The alignment of the data was performed based on retention
indices, second dimension retention times and spectra. After alignment
of the GC × GC–TOFMS data, two ﬁltration criteria was utilized for pos-
itive identiﬁcation: spectral similarity N850 and maximum allowed dif-
ference in retention index between experimental and literature values
b25. Only the metabolites detected in over 70% of the samples in each
of the four study groupswere included in the dataset. This procedure re-
sulted in a total of 465 metabolites. The literature values were obtained
from NIST 2008 Mass Spectral Library or they were determined experi-
mentally with GC × GC-TOFMS instrument in our laboratory with au-
thentic standards (in-house developed library). In addition, Golm
metabolome database (Kopka et al., 2005) was used for further identiﬁ-
cation of the metabolites. In cases where the metabolite identity could
not be determined with available methods, the chemical class was re-
ported based on the MS spectra (Castillo et al., 2011).
The validation and discovery cohorts were analyzed separately.
The orders of both sample preparation and analysis were randomized,
and a set of controls samples (pooled serum samples), standards
and blank samples (solvent blank) was analyzed together with the
samples. In the discovery set, the day-to-day variation of internal
standards added to all samples was on average 17.3% and the day-to-
day variation in control serum samples (n = 31) of the quantiﬁed
metabolites was 18.0%. In the validation set, the variation of internal
standards added to all samples was on average 12.3% and the variation
of control serum samples (n= 14) of the quantiﬁed metabolites was
9.2%.
2.4. Data Filtering
Most severe TBI patients, as well as several moderate and mild TBI
patients and a few controls have been given propofol. Propofol was
detected at low concentrations. However, one phase two metabolite
of propofol (propofol glucuronide) was detected in relatively high
concentrations. The identiﬁcation was further veriﬁed by liquid chro-
matography-quadrupole-time-of-ﬂight mass spectrometry. Possible
correlation of propofol metabolites with other metabolites was also
checked using Pearson correlation, showing correlation with unknown
compounds thatwere structurally similar to the identiﬁed propofol me-
tabolites, and a few additional metabolites. Three compounds that had
similar mass spectra to propofol glucuronide and which showed high
correlation (r N 0.7, p b 0.05) with the compound were removed from
the data. Ibuprofen was also detected in several control samples and
was removed from the dataset.
2.5. Statistical Analyses
All statistical analyses were performed using MATLAB R2014b (The
MathWorks, Inc., Natick, MA, USA), applying in-house developed scripts
and PLS Toolbox 7.9 (Eigenvector Research, Inc., Wenatchee, WA, USA),
and R Statistical Software using rms package (Harrell, 2015).
The zero values in the metabolomics dataset were ﬁrst imputed. For
each metabolite, zero value was replaced by half the minimum non-
zero value of the metabolite across all samples. Due to the non-normal
distribution of data, data were then log-transformed. The mean levels
of the four study groupswere compared usingANOVAon all 465metab-
olites. In order to adjust formultiple testing, FalseDiscovery Rates (FDR)
were calculated (Storey, 2002), with FDR q-values b0.05 considered
signiﬁcant. Themean levels of each of the three TBI groups (mild, mod-
erate, and severe) were compared to the control group using two-sided
t-test (unequal variance).
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on the 172 subjects from the Turku cohort and 98 metabolites selected
using ANOVA and FDR related to control/mild/moderate/severe sub-
jects. Data were autoscaled and the model consisted of seven principal
components. No potential confounding factors, such as age and gender,
affected themodel in themajor components. In the ﬁfth principal com-
ponent there was a slight age drift. Correcting for this drift by orthogo-
nalization did not change the outcome of the model in relation to the
severity status; hence age does not affect the coherence of the metabo-
lites related to the severity of TBI.
2.6. Prediction of Patient Outcomes –Multivariate Metabolite Model
1000 prediction models were built using partial least squares dis-
criminant analysis (PLS-DA). However, PLS-DA is sensitive to a skewed
dataset and therefore 33 subjects were randomly selected out of the 99
good outcome subjects in each of the 1000models in order to alignwith
the 33poor outcome subjects. 49metaboliteswere included in the anal-
yses; these were also selected using ANOVA and FDR related to good/
poor outcome of the subjects. Data were mean centered. The models
were cross-validated using random cross-validation with 10 splits and
10 iterations. During model optimization, metabolites were selected in
two runs as being most important based on variables inﬂuence in pro-
jection (VIP) with values in the ﬁrst run above 1 and in the second
run above 0.75. The most abundant metabolites present in N750 of the
1000 PLS-DAmodels comprised eight metabolites out of the 49 metab-
olites included in the analyses.
2.7. Prediction of Patient Outcomes – Combined Clinical and Metabolite
Model
The additional predictive value of the metabolites over known clin-
ical predictors was assessed with ordinal multivariable regression. Out-
comes were assessed at three months in patients with mild TBI
(Cambridge) and at 6–12 months (all other patients) after the injury
with GOSe. The ﬁrst model contained the clinical predictors age, pupil
reactivity, Glasgow Coma Scale at admission, CT characteristics (Mar-
shall CT classiﬁcation), and extracranial injury (Injury Severity Score).
Selection of these predictors was based on the CRASH prediction
model (MRC Crash Trial Collaborators et al., 2008) but limited to the
availability of variables in our data.
Model 2 contained the same clinical predictors, and the top ranking
metaboliteswere added (top rankingmetabolites based on FDRq-value,
comparing favorable (GOSe N4). and unfavorable (GOSe ≤4) outcomes).
Both models were ﬁtted on the Turku cohort, internally validated using
a bootstrap procedure and subsequently externally validated on the
Cambridge cohort. The best combination of metabolites together with
the clinical predictors was selected recursively, initially starting with
the top ranking metabolite, then adding additional metabolites to the
model, until the predictive performance started to decrease due to the
model complexity.
Missing clinical predictors were imputed with multiple imputation
based on the predictors and outcome, using the AregImpute function
in R. All subsequent analyses were performed on the 10 imputed
datasets and results were pooled in one summary estimate. Models
were compared in terms of the AUC curve.
3. Results
3.1. Serum Metabolites Associate With Severity of TBI
We evaluated serum metabolomic proﬁles from 144 TBI patients
from Turku University Hospital, Turku, Finland. The samples were
taken at the time of hospitalization (arrival samples), which was up to
12 h after the injury. The patients were diagnosed as severe (sTBI;
n = 22), moderate (moTBI; n = 14) or mild TBI (mTBI; n = 108)according to their lowest recorded pre-intubation Glasgow Coma Scale
(GCS) (Saatman et al., 2008) from the scene of accident or emergency
department. Additionally, the control group (n = 28) comprised of
acute orthopedic non-brain injuries (Fig. 1, Table 1). The established
metabolomics platformbased on two-dimensional gas chromatography
coupled to time-of-ﬂightmass spectrometry (GC×GC-TOFMS) (Castillo
et al., 2011) was applied to analyze the serum samples. A total of 465
metabolites were included in the analysis. Among those were amino
acids, sugar derivatives, hydroxyl acids, fatty acids as well as sterols
and related metabolites.
In the arrival samples, 98metabolites showed signiﬁcant differences
between the four study groups in the Turku cohort (ANOVA, FDR
q b 0.05) (Supplemental Table 1). Since the patients could not be con-
trolled for confounding factors such as dietary status, alcohol use and
age, we studied the associations of metabolome with severity of TBI
only for these 98 top rankingmetabolites. Principal component analysis
(PCA) showed that the differences between cases and controls were
most pronounced for the severe and moderate TBI patients, while the
differences were smaller in the mild TBI patients (Fig. 2a, b). None of
the potential confounding factors explained the differences between
the study groups (Materials and Methods). We also speciﬁcally studied
the effect of gender onmetabolite levels in the control group, due to dif-
ferent gender distributions between the control and TBI groups (Table
1). We found no signiﬁcant associations between the 98 top ranking
metabolites and gender (FDR q N 0.25 for all 98 TBI-associated metabo-
lites; two-sided t-test, unequal variance).
Metabolite concentrationswere highly similar in severe andmoder-
ate TBI patients as compared to controls (Fig. 2c). Two medium-chain
fatty acids (FA), octanoic acid (OA) and decanoic acid (DA), 2- and 3-
hydroxybutyric acids as well as several sugar-derived metabolites
were upregulated in sTBI. Among these sugar derivatives, we identiﬁed
a metabolite 2,3-bisphosphoglyceric acid (2,3-BPG), a key regulator
of oxygen release to the tissues (Hsia, 1998), which was strongly
associatedwith severity of TBI. 2,3-BPGwas about 100–fold upregulated
in sTBI and moTBI as compared to controls. However, the levels of 2,3-
BPG was approaching normal levels during the ﬁrst 24 h, unlike
for OA and DA, that remained high in most patients during the ﬁrst
week following the injury (Supplemental Fig. 1). Some metabolites, in-
cluding the amino acids serine and alanine, as well as indole-3-
propionic acid (IPA), were downregulated in TBI (Fig. 2c, Supplemental
Table 1).
Metabolite levels in mild TBI patients followed the same pattern as
in more severe TBI, but the magnitude of change as compared to con-
trols was clearly less than e.g. in sTBI (Fig. 2d). Taken together, these
data suggest that TBI is characterized by a speciﬁc ‘TBI metabotype’,
but the degree ofmetabolite changes as compared to their normal levels
is proportional to the severity of TBI.
3.2. Administration of Propofol Does not AssociateWithObservedMetabolic
Proﬁles in TBI Patients
The propofol vehicle contains predominantly long-chain FAs, mainly
stearic acid, and it is known that propofol may inhibit mitochondrial
entry of long-chain FAs and inhibit the respiratory chain (Wolf et al.,
2001). Although the propofol and related metabolites were removed
from the dataset and the long-chain FAswere not upregulated in the pa-
tientswith propofol administration,we examined inmore detail the po-
tential association of propofol with the observed changes in medium-
chain FA levels. However, the two signiﬁcantly upregulated FAs (OA
and DA) were signiﬁcantly upregulated also in the severe patients
(n= 8) who had not been receiving propofol prior to the ﬁrst sample
being taken (4.2 and 3.6-fold, p = 0.001 and p = 0.012 for OA and
DA, respectively). Furthermore, the single control patient who received
propofol did not show elevated levels of these two FAs. We therefore
concluded that the propofol administration could not explain the ob-
served upregulation of OA and DA in TBI.
Fig. 1.Overview of the workﬂow to studymetabolome in traumatic brain injury (TBI). (a) Serummetabolomics was performed in a series of samples from TBI patients and controls from
the city of Turku, Finland. Signiﬁcant metabolites associated with severity of TBI were identiﬁed. (b) The results from the Turku series were compared with metabolomics data from TBI
patients and controls from the city of Cambridge, UK. (c) Brain microdialysate (BMD) samples were also analyzed from the severe TBI patients in Cambridge, for possible associations of
BMDmetabolite concentrations with the changes observed in serum. (d) In order to assess if metabolites can serve as predictor of outcomes in TBI patients, metabolites from the Turku
dataset were screened for associations with patient outcomes. Predictive models were developed, which were independently tested in the Cambridge dataset.
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Next, we compared the TBI metabolite proﬁles from Turku
with those from a different population from Addenbrooke's Hos-
pital (Cambridge, United Kingdom). The study group comprised
sTBI (n = 23), moTBI (n = 7), mTBI (n = 37) patients and controls
(n = 27), selected using the same inclusion criteria as in the city of
Turku. The metabolomics data was ﬁrst aligned with the Turku dataset
and thus contained a total of 465 metabolites. Out of 98 metabolites
found signiﬁcantly associated with TBI in Turku, 44 were found signiﬁ-
cantly different also in the Cambridge dataset, when comparing sTBI pa-
tients and controls (Supplemental Table 2). There was a high degree of
association between the metabolite levels in sTBI when comparing the
patients from the two cities (Fig. 3a). No such strong association was
found inmTBI,whichmayhave been due to the lack of power in a highly
heterogeneousmTBI population (Supplemental Fig. 2). Notably, theme-
tabolites displaying largest differences between TBI patients and con-
trols in the Turku cohort also behaved similarly in the Cambridge
cohort, including 2,3-BPG and IPA.
In order to study the potential relevance of the serummetabolic pro-
ﬁles in TBI to brain metabolism, brain microdialysates (BMD) were an-
alyzed from 12 samples acquired from four sTBI patients (Cambridge
cohort). The top ranking serum metabolites associated with TBI were
found highly correlated with their levels in BMD (Fig. 3b), which sug-
gests possible disruption of the BBB. Among these metabolites weresugar derivatives, metabolites related to energy metabolism as well as
several hydroxy-acids. Notably, themedium-chain FAs (C7-C10) includ-
ing OA and DA were detected at relatively high concentrations in BMD
as compared to their corresponding concentrations in blood, while the
long-chain FAs had clearly lower levels in BMD than in blood.
3.4. Serum Metabolites Predict TBI Patient Outcomes
We then investigated if the serum metabolome associates with the
patient outcomes as assessed by the Glasgow Outcome Scale Extended
(GOSe) (Wilson et al., 1998). The metabolite levels from patient arrival
samples in the Turku cohort were compared between patients with un-
favorable outcomes (GOSe ≤4; n= 33) and favorable outcomes (GOSe
N4; n = 99). Out of 465 metabolites, 49 were signiﬁcantly different
between the two outcome groups, most of them up-regulated in poor
outcome patients (FDR q b 0.05; Supplemental Table 3), and 26 out of
49 were also signiﬁcantly different and changed to a similar degree in
patients in the two outcome categories in the Cambridge cohort
(Supplemental Fig. 3 and Supplemental Table 4). Only 10 out of 49 me-
tabolites were also among the 98metabolites that were associated with
severity of TBI. Interestingly, despite being strongly associated with TBI
severity, 2,3-BPG was not associated with patient outcomes.
Based on the metabolomics data from 49 metabolites in the Turku
cohort, predictive model was developed using the partial least squares
discriminant analysis (PLS-DA) (Supplemental Table 5). When tested
Fig. 2. Serum metabolome is associated with severity of TBI. (a) Principal Component Analysis (PCA) scores for the ﬁrst two principal components (out of seven), using the
dataset comprising 98 metabolites with FDR q b 0.05. (b) PCA loadings on the ﬁrst two principal components reveal which metabolites are associated with speciﬁc groups in panel a.
(c) Scatter plot of log2 scaled mean metabolite levels in sTBI vs. moTBI patients, with signiﬁcant metabolites in both groups marked with full circles (t-test two sided unequal
variance). (d) Scatter plot of log2 scaled mean metabolite levels in sTBI vs. mTBI patients, with signiﬁcant metabolites in both groups marked with full circles (t-test two sided unequal
variance). Regression lines in panels c and d are drawn based on signiﬁcant metabolites in both groups. In panels b-d, the selected unidentiﬁed metabolites are listed in italic and
annotated according to their structural class (Castillo et al., 2011). Abbreviations: 2,3-BPG, 2,3-bisphosphoglycerate; α-KG, alpha-ketoglutarate; DA, decanoic acid; IPA, indole-3-
propionic acid; moTBI, moderate TBI; mTBI, mild TBI; OA, octanoic acid; PC, principal component; sTBI, severe TBI.
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model predicted the patient outcomes with good accuracy (AUC =
0.84; Fig. 4). We also studied the added value of metabolites over the
established clinical prognostic model CRASH (MRC Crash Trial
Collaborators et al., 2008) using ordinal multivariable regression. The
models were ﬁtted using the Turku data. In external validation in theFig. 3. Serummetabolites found associated with TBI display similar associations in an independ
mean metabolite levels in sTBI patients from the cities of Cambridge vs. Turku, with signiﬁcan
signiﬁcant metabolites in both groups. (b) Comparison of mean serum metabolite level chan
(normalized to mean serum metabolite levels in Controls from Turku), shown as a scatter p
signiﬁcantly associated with TBI in serum (dark blue circles) display a close association with BCambridge cohort, the AUC of the CRASH model was 0.736. When ex-
amining the top ranking metabolites together with the CRASH model
(with metabolites selected based on FDR q-value; Supplemental Table
3; i.e. not optimized together as in the PLS-DA model), the best model
in external validation settingwas achieved for a combination of the clin-
ical model with decanoic acid and pentitol-3-desoxy (AUC = 0.801 inent cohort and are found enriched in brain microdialysates. (a) Scatter plot of log2 scaled
t metabolites in both groups marked with full circles. Regression line is drawn based on
ges (sTBI vs. Controls; Turku) and mean brain microdialysate (BMD) metabolite levels
lot of all metabolites detected both in serum and BMD. The metabolites that are found
MD levels, while the non-associated metabolites (light blue circles) do not.
Fig. 4. Serummetabolite levels at the time of hospitalization predict the patient outcomes
in TBI. Performance of themodel to predict patient outcomes in TBI, shown as ROC curves
for the training (Turku) and validation (Cambridge) data. Abbreviation: AUC, area under
the ROC curve.
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performance over the clinical model. The retention indices and mass
spectra for the two metabolites are shown in Supplemental Table 6.
The predictive performance of a model comprising the twometabolites
alonewas similar as for the clinicalmodel (AUC=0.740 in external val-
idation). Using the univariatemodel ﬁtted to Turku data, individual per-
formance of the two selected metabolites as outcome predictors was
assessed in the validation setting. The two metabolites showed good
performance, with AUC = 0.648 (p b 0.0001) for decanoic acid and
AUC= 0.637 (p b 0.0001) for pentitol-3-desoxy.
4. Discussion
Although several circulating peptide or protein based biomarkers for
TBI have been proposed, these generally lack sensitivity and speciﬁcity.
Herewe showed that speciﬁc circulating bloodmetabolites are associat-
ed with severity of TBI as well as predict the patient outcomes.
We found that two medium-chain fatty acids (OA and DA) are ele-
vated in TBI as well as associated with poor outcomes in TBI patients.
Medium-chain fatty acids readily penetrate the BBB (Oldendorf, 1973)
and there is evidence that FAs can be transported in both directions
through the BBB (Spector, 1988). A recent study of free fatty acids in
plasma and brain, following intravenous human mesenchymal stem
cells transplantation into rats that had undergone transient middle ce-
rebral artery occlusion, showed upregulation of several FAs in both
blood and brain, including OA, whereas the levels of long-chain FAs
were signiﬁcantly reduced (Paik et al., 2009). Mitochondria play a cru-
cial role in the pathophysiology and energy crisis associated with the
brain injury. OA and DA provoke mitochondrial dysfunction by acting
as uncouplers andmetabolic inhibitors of the oxidative phosphorylation
(Schuck et al., 2009b). Several studies have also shown that DA and OA
play a role in brain energymetabolism (Ebert et al., 2003) and elicit lipid
and protein oxidative damage (Green and Reed, 1998; Reis de Assis et
al., 2004; Schuck et al., 2009a).
The observation of increases in plasma 2,3-BPG in the TBI patients,
which was unrelated to the patient outcome, is difﬁcult to interpret
for two reasons. First, blood concentrations of 2,3-BPG are dominated
by the concentration of this metabolite in red blood cells (RBCs),
where it acts as an allosteric modulator of oxygen afﬁnity (Hsia, 1998)
and is produced through the effect of BPG mutase on 1,3-BPG (a glyco-
lytic intermediate). It is therefore likely that plasma levels may be inﬂu-
enced by the dominant effects of RBC 2,3-BPG, but the relationshipbetween the levels of this metabolite in the two compartments is un-
clear. Second, levels of 2,3-BPG in RBCs are modulated by physiological
inﬂuences, including anemia, hypoxia and changes in partial pressure of
carbon dioxide (PaCO2), all of which are common in TBI. These factors
make it difﬁcult to identify the drivers of changes in serum 2,3-BPG,
but may explain why the metabolite had no prognostic relevance.
Several other metabolites, which are present at high concentrations
in cerebrospinal ﬂuid (Hartonen et al., 2013) and BMD,were also upreg-
ulated in serum of the TBI patients, indicative of disruption of the BBB.
These included sugar derivatives, metabolites related to energy metab-
olism as well as several hydroxyl acids. Elevated levels of sugar deriva-
tives are consistent with earlier studies which have shown that
cerebral glucose metabolism is severely disturbed after TBI (Clausen et
al., 2011; Glenn et al., 2003; Hovda et al., 1992).
Althoughmultiple amino acidswere found to be reduced in the plas-
ma of TBI patients when compared to controls, wewere not able to con-
ﬁrm earlier ﬁndings that the levels of branched chain amino acids
(BCAAs) are reduced in TBI (Jeter et al., 2013); which may have been
due to the high variability of BCAA levels due to dietary status not
being controlled for. The indole derivative IPA, a deamination product
of tryptophan formed by gut microbiota (Wikoff et al., 2009), was
downregulated in severe as well as mild TBI patients. IPA has been
shown to prevent oxidative stress and death of primary neurons and
neuroblastoma cells exposed to the amyloid beta-protein (Chyan et
al., 1999). IPA also shows a strong level of neuroprotection in two
other paradigms of oxidative stress (Hwang et al., 2009; Karbownik et
al., 2001). Our ﬁndings thus suggest an intriguing possibility that specif-
ic circulatingmetabolites are transported to the injured brain in order to
maintain normal brain metabolism.
The mean age of the patients in Turku cohort was higher than in
Cambridge cohort. Consequently, the mean GOSe value was lower in
the Turku cohort, which is in accordance with previously published
studies reporting that older age predicts poor prognosis in patients
with TBI (MRC Crash Trial Collaborators et al., 2008; Takala et al.,
2016). The difference in the cohort mean ages likely weakens the total
accuracy of the predictive outcome model. However, the added value
of two among the top ranking metabolites from Turku cohort signiﬁ-
cantly augmented the performance of clinical multivariate model
(CRASH) including age in Cambridge cohort. Considering the discovery
and validation design of the study comprising two distinct TBI cohorts,
the metabolite model appears to be potentially valuable in the clinical
practice.
As a methodological limitation of the present study, several of the
metabolites of interest remained unidentiﬁed. However, using our ana-
lytical approach (Castillo et al., 2011), we were able to annotatemost of
them by their chemical class. Based on the acquired spectra and chro-
matographic information such as retention indices, these metabolites
can still be followed-up in the future when better analytical tools and/
or spectral library information become available. In order to develop a
diagnostic assay based on the biomarker panel identiﬁed in our study,
the metabolites will also have to be absolutely quantiﬁed and then
assayed in larger TBI and control populations. This would serve not
only to validate theﬁndings, but also to derive amore precise diagnostic
model based on the biomarker panel aswell as other relevant clinical in-
formation such as from the CRASH model.
Taken together, we show that TBI is associated with a speciﬁc meta-
bolic proﬁle, which is exacerbated proportionally to the severity of TBI.
High degree of concentration changes of TBI metabolites in serum as
well as their proportional enrichment in BMD is indicative of multiple
underlying mechanisms including potential disruption in BBB as well
as protective response and altered metabolism due to head trauma.
Our ﬁndings also suggest that these metabolites may exhibit diagnostic
potential in the full spectrumof TBI. However, further validation studies
including metabolic proﬁles in patients with polytrauma are needed to
ﬁnd out to what extent the observed results reﬂect systemic responses
to severe injury and to what extent they are brain or TBI-speciﬁc.
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